Related to Horizon Teams Up with U.K.’s ICR to Identify Lethality Genes for Specific Cancers

• RuiYi Licenses mAb Development to China's Genor
  
• Pharma Touting Phase II/III Wins in Run-Up to ASCO
  
• Bayer Prostate Cancer Drug Gains FDA Approval
  
• Ignyta Snaps Up Actagene, Branches into Cancer Rx/Dx
  
• Phase III Failure for Pfizer NHL Drug
  
• NIH Grant Won Toward Developing ASD, Mental Illness Gene-Seeking Software
  
• Mayo Clinic, Cancer Genetics Form Diagnostics JV
  
• OncoMethylome Sciences Inks Biomarker Development Deal with GSK
  
• Celera Licenses Five Cancer-Related Targets to Bayer Schering Pharma
  
• Scientists Uncover Molecular Pathway that Makes Tumors More Aggressive
  
• Serametrix Allies with Ludwig Institute to Exploit Tumor Antigens as Biomarkers
  
• GE and Lilly Develop Prototype to Visualize and Map Cancer Biomarker Networks
  
• Minerva Grants Clarient Exclusive Rights to Develop MUC1* Biomarker for Cancer Diagnostics
  
• Horizon and University of Torino Win $500K Grant to Develop SNP-Based Cancer Models
  
• Horizon Acquires Human Isogenic Cell Models of DNA Damage Repair from University of Minnesota
  
• Broad Institute Taps Complete Genomics to Further Cancer Biomarker Research
  
• Ghent University to Leverage Roche´s LightCycler® 1536 Instrument for Cancer Research
  
• BioMarker Strategies Receives $1M Tranche of SBIR Funding to Develop Solid Tumor Biomarker Platform
  
• Texas Cancer Prevention Organization Awards Rice University $3.7M for Cancer Diagnostic Bio-Nano-Chip
  
• OvaGene Licenses Gene-Expression IP for Development of Clinical Cancer Assays